The US Centers for Disease Control and Prevention recommend that patients with confirmed Zaire ebolavirus not breastfeed their infants to reduce the risk of postnatal transmission of Zaire ebolavirus infection.
No information is available on the use of ansuvimab during breastfeeding. Because ansuvimab is a large protein molecule with a molecular weight of about 147,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[3] Until more data become available, ansuvimab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.